124 related articles for article (PubMed ID: 16847923)
21. Accumulation of MRI contrast agents in malignant fibrous histiocytoma for gadolinium neutron capture therapy.
Fujimoto T; Ichikawa H; Akisue T; Fujita I; Kishimoto K; Hara H; Imabori M; Kawamitsu H; Sharma P; Brown SC; Moudgil BM; Fujii M; Yamamoto T; Kurosaka M; Fukumori Y
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S355-8. PubMed ID: 19386506
[TBL] [Abstract][Full Text] [Related]
22. Potential usefulness of 99mTc-labeled monoclonal antibody A7 for immunoscintigraphy of human pancreatic carcinoma.
Matsumura H; Otsuji E; Kobayashi S; Okamoto K; Toma A; Yamagishi H
Anticancer Res; 2001; 21(5):3433-7. PubMed ID: 11848505
[TBL] [Abstract][Full Text] [Related]
23. Preparation of PEG-conjugated fullerene containing Gd3+ ions for photodynamic therapy.
Liu J; Ohta S; Sonoda A; Yamada M; Yamamoto M; Nitta N; Murata K; Tabata Y
J Control Release; 2007 Jan; 117(1):104-10. PubMed ID: 17156882
[TBL] [Abstract][Full Text] [Related]
24. Gadolinium-loaded polychelating polymer-containing tumor-targeted liposomes.
Erdogan S; Torchilin VP
Methods Mol Biol; 2010; 605():321-34. PubMed ID: 20072891
[TBL] [Abstract][Full Text] [Related]
25. Enhanced tumor localization of radiolabeled Fab fragments of monoclonal antibody A7 in nude mice bearing human pancreatic carcinoma xenografts.
Otsuji E; Yamaguchi T; Yamaoka N; Kato M; Kotani T; Kitamura K; Yamaguchi N; Takahashi T
Jpn J Cancer Res; 1993 Aug; 84(8):914-20. PubMed ID: 8407556
[TBL] [Abstract][Full Text] [Related]
26. Dynamic contrast enhanced MRI of mouse fibrosarcoma using small-molecular and novel macromolecular contrast agents.
Ivanusa T; Beravs K; Medic J; Sersa I; Sersa G; Jevtic V; Demsar F; Mikac U
Phys Med; 2007 Dec; 23(3-4):85-90. PubMed ID: 18061121
[TBL] [Abstract][Full Text] [Related]
27. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.
Gold DV; Goldenberg DM; Karacay H; Rossi EA; Chang CH; Cardillo TM; McBride WJ; Sharkey RM
Cancer Res; 2008 Jun; 68(12):4819-26. PubMed ID: 18559529
[TBL] [Abstract][Full Text] [Related]
28. The gadolinium complexes with polyoxometalates as potential MRI contrast agents.
Li Z; Li W; Li X; Pei F; Li Y; Lei H
Magn Reson Imaging; 2007 Apr; 25(3):412-7. PubMed ID: 17371733
[TBL] [Abstract][Full Text] [Related]
29. Small unilamellar vesicles: a platform technology for molecular imaging of brain tumors.
Iqbal U; Albaghdadi H; Nieh MP; Tuor UI; Mester Z; Stanimirovic D; Katsaras J; Abulrob A
Nanotechnology; 2011 May; 22(19):195102. PubMed ID: 21436507
[TBL] [Abstract][Full Text] [Related]
30. Gd-25 DTPA-MAb, a potential NMR contrast agent for MRI in the xenografted nude mouse: preliminary studies.
Curtet C; Bourgoin C; Bohy J; Saccavini JC; Thédrez P; Akoka S; Tellier C; Chatal JF
Int J Cancer Suppl; 1988; 2():126-32. PubMed ID: 3280506
[TBL] [Abstract][Full Text] [Related]
31. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
Pfost B; Seidl C; Autenrieth M; Saur D; Bruchertseifer F; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
J Nucl Med; 2009 Oct; 50(10):1700-8. PubMed ID: 19793735
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and specificity of a monoclonal antibody-drug conjugate in chemotherapy by intratumoral injection.
Kitamura K; Takahashi T; Miyagaki T; Yamaoka N; Tsurumi H; Ohtsuji E; Kamiguchi M; Noguchi A; Yamaguchi T
Jpn J Cancer Res; 1992 Jul; 83(7):769-74. PubMed ID: 1387634
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.
Kandimalla KK; Wengenack TM; Curran GL; Gilles EJ; Poduslo JF
J Pharmacol Exp Ther; 2007 Aug; 322(2):541-9. PubMed ID: 17505020
[TBL] [Abstract][Full Text] [Related]
34. MR characterization of mild hyperthermia-induced gadodiamide release from thermosensitive liposomes in solid tumors.
Peller M; Schwerdt A; Hossann M; Reinl HM; Wang T; Sourbron S; Ogris M; Lindner LH
Invest Radiol; 2008 Dec; 43(12):877-92. PubMed ID: 19002060
[TBL] [Abstract][Full Text] [Related]
35. Extracellular gadolinium contrast agents: differences in stability.
Morcos SK
Eur J Radiol; 2008 May; 66(2):175-9. PubMed ID: 18343072
[TBL] [Abstract][Full Text] [Related]
36. Assessment of hypoxia in human cervical carcinoma xenografts by dynamic contrast-enhanced magnetic resonance imaging.
Ellingsen C; Egeland TA; Gulliksrud K; Gaustad JV; Mathiesen B; Rofstad EK
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):838-45. PubMed ID: 19215820
[TBL] [Abstract][Full Text] [Related]
37. Molecular coronary MR imaging of human thrombi using EP-2104R, a fibrin-targeted contrast agent: experimental study in a swine model.
Spuentrup E; Katoh M; Wiethoff AJ; Buecker A; Botnar RM; Parsons EC; Guenther RW
Rofo; 2007 Nov; 179(11):1166-73. PubMed ID: 17948194
[TBL] [Abstract][Full Text] [Related]
38. MRI gadolinium-based contrast agents. Radiologists beware!
Goullé JP; Cattanéo A; Saussereau E; Mahieu L; Guerbet M; Lacroix C
Ann Pharm Fr; 2009 Sep; 67(5):335-9. PubMed ID: 19695369
[TBL] [Abstract][Full Text] [Related]
39. Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging: status and clinical potential.
Mohs AM; Lu ZR
Expert Opin Drug Deliv; 2007 Mar; 4(2):149-64. PubMed ID: 17335412
[TBL] [Abstract][Full Text] [Related]
40. Magnetic resonance coronary angiography: comparison between a Gd-BOPTA- and a Gd-DTPA-enhanced spoiled gradient-echo sequence and a non-contrast-enhanced steady-state free-precession sequence.
Nassenstein K; Breuckmann F; Hunold P; Barkhausen J; Schlosser T
Acta Radiol; 2009 May; 50(4):406-11. PubMed ID: 19308763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
